EXEL discovers, develops, and commercializes new treatments for hard-to-treat cancers. Its second-quarter 2026 report showed $629 million in quarterly revenue ($573 million from its cabozantinib product (CABOMETYX) alone, a 10% year-over-year rise), GAAP net income of $212 million ($0.82 per diluted share), $1.4 billion in cash, and $312 million in repurchases last quarter. The company reports again on Oct. 29.
It’s no wonder EXEL shares are up 42% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the forward picture of the stock.
Exelixis, a Big Money Buy
Institutional volumes reveal plenty. In the last year, EXEL has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.
Exelixis Fundamental Analysis
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:
- 3-year sales growth rate (+13%)
- 3-year EPS growth rate (+83.6%)
Source: FactSet
Also, EPS is estimated to ramp higher this year by +17.8%.
Now it makes sense why the stock has been generating Big Money interest. EXEL has a track record of strong financial performance.
Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.
Exelixis has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
It’s made the rare Outlier 20 report 34 times since 2017, rising 177% since the first outlier inflow signal. The blue bars below show when EXEL was a top pick in the last year…institutions love this stock:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Exelixis Price Prediction
The EXEL action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in EXEL at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.